Shamburg News · 8-K filed Oct 23, 2026, 4:05 PM EDT
MacroGenics Reports Positive Interim Phase 1 Results for MGC026 at ESMO 2026
MGNX · MACROGENICS INC
- Other event
- Materiality: medium
On October 23, 2026, MacroGenics issued a press release reporting interim Phase 1 data for MGC026, a B7-H3-directed antibody-drug conjugate, in advanced solid tumors, presented at the ESMO 2026 Congress in Madrid. The filing reports a 27% best overall response rate (6/22 patients) in heavily pretreated squamous cell carcinoma of the head and neck (SCCHN) patients, and a plan to initiate a front-line SCCHN expansion cohort with pembrolizumab in early 2027. The Company also posted a slide presentation, furnished as Exhibit 99.2.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001125345-26-000066.
Written from the filing by Shamburg Markets. Figures are as reported by the company.